Fatty analogues for the treatment of obesity, hypertension and fatty liver

A method for producing weight loss or a reduction of the fat mass in a human or non-human animal comprising administering a therapeutically effective amount of a composition comprising at least one fatty acid analogue of the general formula (I)

• CH3—[CH2]m—[Xi—CH2]n—COOR
• wherein
• n is an integer from 1 to 12, and
• m is an integer from 0 to 23, and
• i is an odd number which indicates the position relative to COOR, and
• each Xi is independently selected from the group consisting of O, S, SO, SO2, Se, and CH2, and
• R represents hydrogen or C1-C4 alkyl,
• with the proviso that at least one of the Xi is not CH2, or a salt, prodrug, or complex thereof.

A method for the modification of the fat distribution and content of an animal, comprising administering to the animal food or a feed product comprising at least one fatty acid analogue of the general formula (I)

• CH3—[CH2]m—[Xi—CH2]n—COOR
• wherein
• n is an integer from 1 to 12, and
• m is an integer from 0 to 23, and
• i is an odd number which indicates the position relative to COOR, and
• each Xi is independently selected from the group consisting of O, S, SO, SO2, Se, and CH2, and
• R represents hydrogen or C1-C4 alkyl,
• with the proviso that at least one of the Xi is not CH2, or a salt, prodrug, or complex thereof.

A method for the treatment or prevention of hypertension, comprising administering to an animal in need thereof a therapeutically effective amount of at least one fatty acid analogue of the general formula (I)

• CH3—[CH2]m—[Xi—CH2]n—COOR
• wherein
• n is an integer from 1 to 12, and
• m is an integer from 0 to 23, and
• i is an odd number which indicates the position relative to COOR, and each Xi is independently selected from the group consisting of O, S, SO, SO2, Se, and CH2, and
• R represents hydrogen or C1-C4 alkyl,
• with the proviso that at least one of the Xi is not CH2, or a salt, prodrug, or complex thereof.

A method for the treatment or prevention of fatty hepatosis, comprising administering to an animal in need thereof a therapeutically effective amount of at least one fatty acid analogue of the general formula (I)

• CH3—[CH2]m—[Xi—CH2]n—COOR
• wherein
• n is an integer from 1 to 12, and
• m is an integer from 0 to 23, and
• i is an odd number which indicates the position relative to COOR, and each Xi is independently selected from the group consisting of O, S, SO, SO2, Se, and CH2, and
• R represents hydrogen or C1-C4 alkyl,
• with the proviso that at least one of the Xi is not CH2, or a salt, prodrug, or complex thereof.

A method for the treatment or prevention of a metabolic syndrome characterized by hyperinsulinemia, insulin resistance, obesity, glucose intolerance, Type 2 diabetes mellitus, dyslipdemia and hypertension, comprising administering to an animal in need thereof a therapeutically effective amount of at least one fatty acid analogue of the general formula (I)

• CH3—[CH2]m—[Xi—CH2]n—COOR
• wherein
• n is an integer from 1 to 12, and
• m is an integer from 0 to 23, and
• i is an odd number which indicates the position relative to COOR, and each Xi is independently selected from the group consisting of O, S, SO, SO2, Se, and CH2, and
• R represents hydrogen or C1-C4 aklyl,
• with the proviso that at least one of the Xi is not CH2, or a salt, prodrug, or complex thereof.

A fatty acid analogue of the general formula (I)

• CH3—[CH2]m—[Xi—CH2]n—COOR
• wherein
• n is an integer from 1 to 12, and
• m is an integer from 0 to 23, and
• i is an odd number which indicates the position relative to COOR, and each Xi is independently selected from the group consisting of O, S, SO, SO2, Se, and CH2, and
• R represents hydrogen or C1-C4 alkyl,
• with the proviso that at least one of the Xi is not CH2, and that if there is only 1 Xi that is not —CH2—, then Xi=3 is CH2,
• or a salt, prodrug, or complex thereof.

A pharmaceutical composition for the prevention and treatment of obesity in animals comprising a fatty acid analogue of the general formula (I)

• CH3—[CH2]m—[Xi—CH2]n—COOR
• wherein
• n is an integer from 1 to 12, and
• m is an integer from 0 to 23, and
• i is an odd number which indicates the position relative to COOR, and each Xi is independently selected from the group consisting of O, S, SO, SO2, Se, and CH2, and
• R represents hydrogen or C1-C4 aklyl,
• with the proviso that at least one of the Xi is not CH2, and that if there is only 1 Xi that is not —CH2—, then Xi=3 is CH2,
• or a salt, prodrug, or complex thereof, and a pharmaceutically acceptable carrier or excipient.

A nutritional composition comprising an amount of fatty acid analogue of the general formula (I)

• CH3—[CH2]m—[Xi—CH2]n—COOR
• wherein
• n is an integer from 1 to 12, and
• m is an integer from 0 to 23, and
• i is an odd number which indicates the position relative to COOR, and
• each Xi is independently selected from the group consisting of O, S, SO, SO2, Se, and CH2, and
• R represents hydrogen or C1-C4 alkyl, or a salt, prodrug, or complex thereof,
• with the proviso that at least one of the Xi is not CH2, and that if there is only 1 Xi that is not —CH2—, then Xi=3 is CH2,
• and the amount of the fatty acid analogue is effective to reduce or maintain the total body weight or total body fat mass in an animal.